OBJECTIVE: To explore the correlation of serum adropin level with coronary artery disease (CAD). METHODS: According to coronary angiography, 356 consecutive patients with chest complaints from January 2011 to July 2012 were divided into 2 groups of CAD (n = 264, with CAD) and control (n = 92, without CAD). The serum adropin level and other CAD related metabolic parameters were measured and SYNTAX score was calculated. RESULTS: Serum adropin level was significantly lower in group CAD than that in control group ((56 ± 15) vs (83 ± 10) ng/L, P < 0.01).Serum adropin levels in high, mild, low SYNTAX score group were (60 ± 22),(56 ± 12),(54 ± 10) ng/L respectively, and there was no significant difference among 3 groups(P = 0.116). Multivariate regression analysis revealed that adropin was an independent risk factor for CAD (OR = 0.849, 95%CI:0.817-0.882, P < 0.01). CONCLUSIONS: Lower serum adropin level is significantly associated with CAD. Thus it indicates a possible role of adropin in the prevention of CAD.
OBJECTIVE: To explore the correlation of serum adropin level with coronary artery disease (CAD). METHODS: According to coronary angiography, 356 consecutive patients with chest complaints from January 2011 to July 2012 were divided into 2 groups of CAD (n = 264, with CAD) and control (n = 92, without CAD). The serum adropin level and other CAD related metabolic parameters were measured and SYNTAX score was calculated. RESULTS: Serum adropin level was significantly lower in group CAD than that in control group ((56 ± 15) vs (83 ± 10) ng/L, P < 0.01).Serum adropin levels in high, mild, low SYNTAX score group were (60 ± 22),(56 ± 12),(54 ± 10) ng/L respectively, and there was no significant difference among 3 groups(P = 0.116). Multivariate regression analysis revealed that adropin was an independent risk factor for CAD (OR = 0.849, 95%CI:0.817-0.882, P < 0.01). CONCLUSIONS: Lower serum adropin level is significantly associated with CAD. Thus it indicates a possible role of adropin in the prevention of CAD.
Authors: Alicja E Grzegorzewska; Leszek Niepolski; Monika K Świderska; Adrianna Mostowska; Ireneusz Stolarek; Wojciech Warchoł; Marek Figlerowicz; Paweł P Jagodziński Journal: BMC Med Genet Date: 2018-11-09 Impact factor: 2.103